The investor presentation “MagSense® Technology: A New Diagnostic for Targeted Early Detection of Cancer” was presented at the 2017 Annual General Meeting. View the Investor Presentation.
Imagion Biosystems receives AU$3.5 million in R&D tax incentives
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report that it